Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study

G Ferrandina12 M Ludovisi1 R De Vincenzo1 V Salutari1 D Lorusso2 M Colangelo3 T Prantera4 MR Valerio5 and G Scambia2

首页> 外文期刊>Annals of Oncology >Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study

【24h】

Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study

机译：多西他赛和奥沙利铂在铂敏感性复发性卵巢癌的二线治疗中：II期研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: A prospective phase II study was conducted to evaluate the efficacy and toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) >12 months.

机译：背景：一项前瞻性II期研究旨在评估多西他赛（Taxotere）（DTX）和奥沙利铂（OXA）联合治疗在无铂间隔（PFI）> 12个月后复发的卵巢癌患者中的疗效和毒性。

著录项

来源
《Annals of Oncology 》 |2007年第8期| 1348-1353| 共6页
作者
G Ferrandina12 M Ludovisi1 R De Vincenzo1 V Salutari1 D Lorusso2 M Colangelo3 T Prantera4 MR Valerio5 and G Scambia2;
展开▼
作者单位

Gynecologic Oncology Unit Catholic University of Rome Rome;

Department of Oncology Catholic University of Campobasso Campobasso;

Medical Oncology SS. Annunziata Hospital Sulmona;

Medical Oncology San Giovanni di Dio Hospital Crotone;

Department of Oncology University of Palermo Palermo Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. [J] . Ferrandina G, Ludovisi M, De-Vincenzo R, Annals of oncology: official journal of the European Society for Medical Oncology . 2007 ,第8期

机译：多西他赛和奥沙利铂在铂敏感性复发性卵巢癌的二线治疗中：II期研究。
2. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. [J] . Viens P, Petit T, Yovine A, Annals of oncology: official journal of the European Society for Medical Oncology . 2006 ,第3期

机译：紫杉醇和奥沙利铂联合治疗对铂敏感的复发性晚期卵巢癌患者的II期研究。
3. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. [J] . Viens P, Petit T, Yovine A, Annals of oncology: official journal of the European Society for Medical Oncology . 2006 ,第3期

机译：紫杉醇和奥沙利铂联合治疗对铂敏感的复发性晚期卵巢癌患者的II期研究。
4. Efficacy of combination chemotherapy with docetaxel and irinotecan as first- or second-line treatment for advanced gastric cancer [C] . K. Sugiyama, A. Ishikawa, T. Watanabe International Gastric Cancer Congress . 2009

机译：组合化疗与多西紫杉醇和伊替康的疗效，作为晚期胃癌的第一或二线治疗
5. Development of Novel Approaches for the Treatment of Recurrent Ovarian Cancer [D] . Mohammadali Pourmalekshah, Obeid. 2020

机译：新型卵巢癌治疗新方法的发展
6. A phase II evaluation of Irofulven (IND#55804 NSC#683863) as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group trial [O] . Russell J. Schilder, John A. Blessing, Mark S. Shahin, -1

机译：Irofulven的相II评价（IND＃55804NsC＃683863）作为二线治疗复发性或持续性中间铂敏感卵巢癌或原发性腹膜癌的：一个妇科肿瘤组试验
7. CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase 2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer [O] . Jung-Min eLee, Jane B. Trepel, Peter eChoyke, 2015

机译：CECs和IL-8在复发性铂敏感性卵巢癌患者中具有预后和预测效用：生物标志物与olaparib和西地尼布与复发性铂敏感性卵巢癌中olaparib的随机2期试验相关

Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study

摘要

著录项

相似文献

相关主题

期刊订阅